# Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

> **NCT01520220** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 100 (actual)

## Conditions studied

- Myeloproliferative Neoplasms of
- Polycythemia Vera
- Essential Thrombocythemia
- Myelofibrosis

## Interventions

- **DRUG:** LY2784544

## Key facts

- **NCT ID:** NCT01520220
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-11
- **Primary completion:** 2015-06-26
- **Final completion:** 2017-02-24
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2017-04-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01520220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01520220, "Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01520220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*